The drugmaker's Q2 earnings rose 9% to 48 cents a share, beating by 4 cents. Revenue fell 4% to $3.89 bil, topping estimates for $3.85 bil. Bristol-Myers Squibb (BMY), which is moving away from mainly making pills to treat everyday illnesses to developing complex, expensive drugs for cancer and rare disorders, guided full-year '14 EPS to $1.70-$1.80, with the midpoint below estimates for $1.77. Shares rose 0.3% to 49.46.
"We are not very ambitious. I should be careful about talking about work-life balance, but the Americans just work harder.”
In his 2016 letter to Berkshire Hathaway shareholders, legendary investor Warren Buffett wrote, “Every decade or so, dark clouds will fill the economic skies, and they will briefly rain gold. When downpours of that sort occur, it’s imperative that we ...
As US growth shows signs of sputtering and inflation keeps rising, a re-run of the tumultuous 1970s is looking more likely.
The combination of artificial intelligence (AI) and cybersecurity is a match made in heaven.
Intel stock dropped 9% after the company reported Q1 earnings. Is it a buy right now?
Rooting for Donald Trump to fail has rarely been this profitable. Just ask a hardy band of mostly amateur Wall Street investors who have collectively made tens of millions of dollars over the past month by betting that the stock price of his social media business — Truth Social — will keep dropping despite massive buying by Trump loyalists and wild swings that often mirror the candidate’s latest polls, court trials and outbursts on Trump Social itself.
Microsoft reported better than anticipated Q3 earnings on Thursday, powered by growth in its cloud products.
Gross said in a post on X to avoid tech, but if you have to invest in the sector, one name stands out.
These stocks appear to be the most magnificent of all in the billionaire hedge fund manager's eyes.
This company told investors it might go out of business.